Clinical stage generative AI-driven drug discovery company Insilico Medicine has today published a paper on a new multimodal transformer-based aging clock; the new clock is capable of processing diverse data sets and providing insights into biomarkers for aging, mapping them to genes relevant to both aging and disease, and discovering new therapeutic targets to slow or reverse both aging and aging-related diseases.
Insilico calls the aging clock Precious1GPT, in a nod to the powerful “One Ring” in Tolkien’s Lord of the Rings; the findings have been published in the journal Aging.
Longevity. Technology: Insilico has been at the forefront of both generative AI and aging research, and has been publishing studies on biomarkers of aging using advanced bioinformatics since 2014. Later, the company trained deep neural networks (DNNs) on human “multi-omics” longitudinal data and retrained them on diseases to develop its end-to-end Pharma. AI platform for target discovery, drug design, and clinical trial prediction.
Comments are closed.